Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 342

1.

Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review.

Calzetta L, Ritondo BL, Matera MG, Cazzola M, Rogliani P.

Expert Rev Respir Med. 2020 Mar 13. doi: 10.1080/17476348.2020.1743180. [Epub ahead of print]

PMID:
32168461
2.

The effect of doxofylline in asthma and COPD.

Cazzola M, Matera MG.

Respir Med. 2020 Apr;164:105904. doi: 10.1016/j.rmed.2020.105904. Epub 2020 Feb 19. Review.

PMID:
32094104
3.

TSLP Inhibitors for Asthma: Current Status and Future Prospects.

Matera MG, Rogliani P, Calzetta L, Cazzola M.

Drugs. 2020 Apr;80(5):449-458. doi: 10.1007/s40265-020-01273-4.

PMID:
32078149
4.

α1-Antitrypsin deficiency and chronic respiratory disorders.

Cazzola M, Stolz D, Rogliani P, Matera MG.

Eur Respir Rev. 2020 Feb 12;29(155). pii: 190073. doi: 10.1183/16000617.0073-2019. Print 2020 Mar 31. Review.

5.

Severe Asthma and Biological Therapy: When, Which, and for Whom.

Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M.

Pulm Ther. 2019 Dec 26. doi: 10.1007/s41030-019-00109-1. [Epub ahead of print] Review.

PMID:
32048241
6.

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Pulm Ther. 2019 Dec;5(2):117-126. doi: 10.1007/s41030-019-00102-8. Epub 2019 Nov 2. Review.

7.

A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma.

Matera MG, Rinaldi B, Berardo C, Rinaldi M, Cazzola M.

Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):143-148. doi: 10.1080/17425255.2020.1716730. Epub 2020 Jan 30. Review.

PMID:
31958237
8.

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.

Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P.

Pulm Pharmacol Ther. 2020 Feb;60:101883. doi: 10.1016/j.pupt.2019.101883. Epub 2019 Dec 26.

9.

The future of bronchodilation: looking for new classes of bronchodilators.

Cazzola M, Rogliani P, Matera MG.

Eur Respir Rev. 2019 Dec 23;28(154). pii: 190095. doi: 10.1183/16000617.0095-2019. Print 2019 Dec 31. Review.

10.

Pharmacology and Therapeutics of Bronchodilators Revisited.

Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M.

Pharmacol Rev. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150. Review.

PMID:
31848208
11.

Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.

Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L.

Br J Pharmacol. 2020 Mar;177(5):1150-1163. doi: 10.1111/bph.14909. Epub 2020 Jan 29.

PMID:
31660611
12.

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

Calzetta L, Matera MG, Cazzola M, Rogliani P.

Adv Ther. 2019 Dec;36(12):3291-3298. doi: 10.1007/s12325-019-01119-w. Epub 2019 Oct 25.

13.

Isolated airways in equine respiratory pharmacology: They never lie.

Calzetta L, Pistocchini E, Ritondo BL, Roncada P, Cito G, Britti D, Matera MG.

Pulm Pharmacol Ther. 2019 Dec;59:101849. doi: 10.1016/j.pupt.2019.101849. Epub 2019 Sep 22.

PMID:
31553927
14.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Dec;59:101841. doi: 10.1016/j.pupt.2019.101841. Epub 2019 Sep 11.

PMID:
31520718
15.

Pharmacological treatment and current controversies in COPD.

Cazzola M, Rogliani P, Stolz D, Matera MG.

F1000Res. 2019 Aug 29;8. pii: F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019. Review.

16.

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1. Review.

PMID:
31474120
17.

Ultra-LABAs for the treatment of asthma.

Cazzola M, Rogliani P, Matera MG.

Respir Med. 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005. Epub 2019 Aug 12. Review.

PMID:
31425937
18.

A potential role of triple therapy for asthma patients.

Cazzola M, Puxeddu E, Matera MG, Rogliani P.

Expert Rev Respir Med. 2019 Nov;13(11):1079-1085. doi: 10.1080/17476348.2019.1657408. Epub 2019 Sep 1.

PMID:
31422716
19.

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG.

Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019.

20.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M.

Pulm Pharmacol Ther. 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828. Epub 2019 Jul 23. Review.

PMID:
31349002
21.

Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.

Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D.

Respir Med. 2019 Jul - Aug;154:86-92. doi: 10.1016/j.rmed.2019.06.015. Epub 2019 Jun 18.

PMID:
31228775
22.

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27. Review.

PMID:
31147200
23.

Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.

Matera MG, Calzetta L, Rogliani P, Cazzola M.

Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. Review.

PMID:
31136930
24.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.

Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.

25.

Monoclonal antibodies in severe asthma: is it worth it?

Calzetta L, Matera MG, Rogliani P.

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):517-520. doi: 10.1080/17425255.2019.1621837. Epub 2019 May 23.

PMID:
31104515
26.

Response.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 May;155(5):1079-1080. doi: 10.1016/j.chest.2019.01.028. No abstract available.

PMID:
31060694
27.

Bronchodilators in subjects with asthma-related comorbidities.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Respir Med. 2019 May;151:43-48. doi: 10.1016/j.rmed.2019.04.001. Epub 2019 Apr 3. Review.

PMID:
31047116
28.

Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.

Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG.

Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.

PMID:
30876907
29.

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J.

Expert Opin Pharmacother. 2019 Apr;20(6):737-750. doi: 10.1080/14656566.2019.1570133. Epub 2019 Feb 1. Review.

PMID:
30707637
30.

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17. Review.

PMID:
30660781
31.

Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.

Cazzola M, Page C, Calzetta L, Matera MG.

Pharm Pat Anal. 2018 Nov;7(6):249-257. doi: 10.4155/ppa-2018-0030. Epub 2019 Jan 18.

PMID:
30657422
32.

The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement.

Nigro E, Stiuso P, Matera MG, Monaco ML, Caraglia M, Maniscalco M, Perrotta F, Mazzarella G, Daniele A, Bianco A.

Pulm Pharmacol Ther. 2019 Apr;55:25-30. doi: 10.1016/j.pupt.2019.01.004. Epub 2019 Jan 15.

PMID:
30654148
33.

Varenicline for long term smoking cessation in patients with COPD.

Hernández Zenteno RJ, Lara DF, Venegas AR, Sansores RH, Pineda JR, Trujillo FF, Pérez Padilla JR, Matera MG, Cazzola M.

Pulm Pharmacol Ther. 2018 Dec;53:116-120. doi: 10.1016/j.pupt.2018.11.001. Epub 2018 Nov 3.

PMID:
30399395
34.

Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents.

Matera MG, Rogliani P, Ora J, Cazzola M.

Expert Opin Pharmacother. 2018 Dec;19(18):2043-2053. doi: 10.1080/14656566.2018.1534957. Epub 2018 Oct 25. Review.

PMID:
30359143
35.

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801586. doi: 10.1183/13993003.01586-2018. Print 2018 Dec.

PMID:
30309975
36.

Rebuttal From Drs Cazzola and Matera.

Cazzola M, Matera MG.

Chest. 2018 Oct;154(4):751-752. doi: 10.1016/j.chest.2018.06.023. No abstract available.

PMID:
30290927
37.

POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes.

Cazzola M, Matera MG.

Chest. 2018 Oct;154(4):746-748. doi: 10.1016/j.chest.2018.06.022. No abstract available.

PMID:
30290925
38.

Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease.

Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M.

Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1101-1111. doi: 10.1080/17425255.2018.1530215. Epub 2018 Oct 9. Review.

PMID:
30261755
39.

Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.

Calzetta L, Matera MG, Rogliani P, Cazzola M.

Expert Rev Respir Med. 2018 Aug;12(8):693-708. doi: 10.1080/17476348.2018.1495562. Epub 2018 Jul 17. Review.

PMID:
29972340
40.

Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?

Cazzola M, Matera MG, Rogliani P, Calzetta L.

Expert Opin Investig Drugs. 2018 Jul;27(7):573-581. doi: 10.1080/13543784.2018.1492548. Epub 2018 Jul 4. Review.

PMID:
29972333
41.

Combining Dual Bronchodilation and β-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases.

Cazzola M, Matera MG.

Chest. 2018 Jun;153(6):1289-1291. doi: 10.1016/j.chest.2018.01.032. No abstract available.

PMID:
29884246
42.

Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air.

Cazzola M, Matera MG.

Curr Opin Pharmacol. 2018 Jun;40:iv-viii. doi: 10.1016/j.coph.2018.05.011. Epub 2018 May 30. No abstract available.

PMID:
29859765
43.

Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells.

Matera MG, Calzetta L, Gritti G, Gallo L, Perfetto B, Donnarumma G, Cazzola M, Rogliani P, Donniacuo M, Rinaldi B.

Eur J Pharmacol. 2018 Aug 5;832:114-119. doi: 10.1016/j.ejphar.2018.05.023. Epub 2018 May 18.

PMID:
29782855
44.

β2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases.

Matera MG, Page C, Rinaldi B.

Curr Opin Pharmacol. 2018 Jun;40:142-146. doi: 10.1016/j.coph.2018.04.012. Epub 2018 May 12. Review.

PMID:
29763833
45.

Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?

Liccardi G, Calzetta L, Milanese M, Salzillo A, Apicella G, Matera MG, Rogliani P.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1093-1094. doi: 10.1016/j.jaip.2018.01.029. No abstract available.

PMID:
29747978
46.

The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.

Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L.

Expert Opin Drug Saf. 2018 Jun;17(6):589-596. doi: 10.1080/14740338.2018.1472232. Epub 2018 May 14. Review.

PMID:
29716427
47.

Impact of doxofylline in COPD: A pairwise meta-analysis.

Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG.

Pulm Pharmacol Ther. 2018 Aug;51:1-9. doi: 10.1016/j.pupt.2018.04.010. Epub 2018 Apr 26. Review.

48.

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P.

Respir Res. 2018 Apr 12;19(1):65. doi: 10.1186/s12931-018-0770-7.

49.

N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.

Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG.

Biomed Pharmacother. 2018 Jul;103:1-8. doi: 10.1016/j.biopha.2018.04.011. Epub 2018 Apr 24.

50.

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy.

Calzetta L, Matera MG, Cazzola M.

Curr Opin Pharmacol. 2018 Jun;40:95-103. doi: 10.1016/j.coph.2018.03.011. Epub 2018 Apr 4. Review.

PMID:
29626716

Supplemental Content

Loading ...
Support Center